Ossiam Increases Holdings in Zoetis Inc. $ZTS

Key Points

• Ossiam boosted its stake in Zoetis by 608.3% in Q3, adding 107,562 shares for a total of 125,245 shares valued at $18,326,000.
• Zoetis beat quarterly estimates with $1.48 EPS vs. $1.40 and revenue of $2.39B (up 3% YoY), and set FY2026 guidance of $7.00–$7.10 EPS; the stock has a market cap of about $48.8B and a P/E of 19.21.
• The company declared a quarterly dividend of $0.53 (annualized $2.12, ~1.8% yield), institutional investors hold about 92.8% of shares, and analysts' consensus rating is "Hold" with an average target of $152.91.

Ossiam boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 608.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 125,245 shares of the company's stock after buying an additional 107,562 shares during the quarter. Ossiam's holdings in Zoetis were worth $18,326,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of the business. North Star Asset Management Inc. grew its stake in Zoetis by 4.9% during the 2nd quarter. North Star Asset Management Inc. now owns 1,441 shares of the company's stock worth $225,000 after purchasing an additional 67 shares in the last quarter. Bank of Nova Scotia Trust Co. increased its holdings in Zoetis by 4.6% in the second quarter. Bank of Nova Scotia Trust Co. now owns 1,692 shares of the company's stock valued at $264,000 after buying an additional 74 shares during the last quarter. Summit Place Financial Advisors LLC increased its holdings in Zoetis by 0.4% in the third quarter. Summit Place Financial Advisors LLC now owns 19,369 shares of the company's stock valued at $2,834,000 after buying an additional 76 shares during the last quarter. First County Bank CT raised its stake in Zoetis by 5.4% in the third quarter. First County Bank CT now owns 1,535 shares of the company's stock valued at $225,000 after buying an additional 79 shares in the last quarter. Finally, CWA Asset Management Group LLC lifted its holdings in Zoetis by 1.1% during the 3rd quarter. CWA Asset Management Group LLC now owns 7,236 shares of the company's stock worth $1,059,000 after buying an additional 80 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of Zoetis stock opened at $115.62 on Friday. The firm's fifty day simple moving average is $125.34 and its 200-day simple moving average is $131.91. Zoetis Inc. has a 12 month low of $114.47 and a 12 month high of $172.23. The stock has a market capitalization of $48.81 billion, a price-to-earnings ratio of 19.21, a PEG ratio of 1.76 and a beta of 0.95. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, topping analysts' consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to analysts' expectations of $2.36 billion. During the same quarter in the prior year, the business earned $1.40 EPS. Zoetis's quarterly revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis's dividend payout ratio (DPR) is currently 35.22%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ZTS. Bank of America upped their price objective on Zoetis from $135.00 to $140.00 and gave the stock a "neutral" rating in a research report on Friday, February 13th. Weiss Ratings upgraded Zoetis from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday. The Goldman Sachs Group upgraded shares of Zoetis to a "buy" rating in a research note on Monday, December 15th. Leerink Partners reissued a "market perform" rating on shares of Zoetis in a report on Tuesday. Finally, Piper Sandler restated a "neutral" rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Six equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $152.91.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.